Healthy Living: Clinical Trial Drug For Triple Negative Breast Cancer

Triple Negative Breast Cancer accounts for about 15% of all new breast cancer cases in the US, but it leads to 25% of all breast cancer deaths.

It's an aggressive cancer that, until now, has only been treated with standard chemo.  
Doctor Gralow says one downside of the PARP inhibitors is they are very expensive.
While still in clinical trials, she estimates they might cost between $2,000 and $10,000 a month, if they hit the market. 
The next step for this research is a larger clinical trial that will test the drug on more patients. 
During the clinical trial, patients get the drug for free.
Michelle Dunaway shows us a new therapy that's offering patients hope for the first time.